ClinicalTrials.gg
CompletedNCT01822041Updated Sep 13, 2013

14C-ARN-509 Microtracer Label AME and Absolute BA Study

A Phase 1 interventional study of ARN-509 in Healthy, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 1 site in Netherlands. Open to male participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-13.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
Male
01

Study summary

This is study in healthy human volunteers to determine the absorption, metabolism, and excretion (AME) profile of ARN-509 as well as its absolute oral bioavailability (BA).

Read the detailed description

Two cohorts of 6 healthy volunteers will be enrolled for the AME and absolute BA parts, respectively. The dose for both cohorts is 240 mg. The expected exposure of the dose is 7-fold lower than the steady state reached in patients with castration-resistant prostate cancer.

02

Conditions studied

  • Healthy

Keywords

  • healthy volunteers
  • mass balance study
  • Pharmacokinetics
03

In context

Lead sponsor

Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.

Unclear whether first submitted before or after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Gender : male
  2. Age : 50 - 80 years, inclusive
  3. (BMI) : 18.5-30.0 kg/m2
  4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, "power drinks"), grapefruit (juice) and tobacco products from 48 h prior to entry in the clinical research center until discharge
  5. Medical history without major pathology

Key Exclusion Criteria:

  1. Evidence of pathology.
  2. Mental handicap.
  3. History of relevant drug and/or food allergies.
  4. Regular/routine treatment with non-topical medications within 30 days prior to entry into the clinical research center.
  5. Smoking.
  6. History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
  7. Use of concomitant medication, except for acetaminophen (paracetamol) and topical medications
  8. Irregular defecation pattern (less than once per 2 days).
  9. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, and alcohol).
  10. Intake of more than 24 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits).
  11. Positive screen on , anti- or anti- 1/2.
  12. Illness within five days prior to drug administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Part A - 14C labeled ARN-509

    Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509

    Drug: ARN-509

  • Active comparator
    Part B: 14C labeled ARN-509

    Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509

    Drug: ARN-509

Interventions

  • Single oral dose of 240 mg ARN-509

06

What researchers measure

Primary outcomes

  1. Mass Balance

    To determine the rate and routes of excretion of ARN-509 in urine, feces, and expired air

    Time frame: 2 months 10 days

  2. Absolute Oral Bioavailability

    To determine absolute oral bioavailability of ARN-509

    Time frame: 2 months 10 days

Secondary outcomes

  1. Metabolite Profile

    To identify and quantify the ARN-509 metabolites in plasma, urine, and feces

    Time frame: 2 months 10 days

07

Study locations

1 site
  • PRA - Clinical Research Unit, University Medical Centre Groningen
    Groningen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2013
First posted
Apr 2, 2013
Start
Mar 2013
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Sep 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01822041
Responsible party
Sponsor
First posted
Apr 2, 2013
Start date
Mar 2013
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Sep 13, 2013

Study contacts

Nada al Kotbi, MD
principal investigator · PRA International Group BV
Helen Pruim-Tait, MA, MSc
study director · PRA International Group BV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion